Severe persistent allergic asthma

Anna Bodzenta-Łukaszyk; Roman Skiepko; Danuta Lenczewska; Ziemowit Ziętkowski

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2009
vol. 26

Send email

Copy url:

abstract:

Severe persistent allergic asthma

Anna Bodzenta-Łukaszyk

,

Roman Skiepko

,

Danuta Lenczewska

,

Ziemowit Ziętkowski

Post Dermatol Alergol 2009; XXVI, 5: 329–330

Online publish date: 2009/10/19

View full text Get citation

Asthma is a chronic inflammatory disease of the airways. Approximately 60% of asthma cases can be attributed to allergic asthma. The aim of this article is to present the current results concerning the problem of severe persistent allergic asthma, the use of anti-IgE treatment (omalizumab) as well as our own results determining the clinical efficacy and anti-inflammatory activity of Xolair (omalizumab) in patients with severe allergic asthma.

keywords:

Severe persistent allergic asthma

Anna Bodzenta-Łukaszyk , Roman Skiepko , Danuta Lenczewska , Ziemowit Ziętkowski

severe persistent allergic asthma, omalizumab

Anna Bodzenta-Łukaszyk

,

Roman Skiepko

,

Danuta Lenczewska

,

Ziemowit Ziętkowski